Akebia Refinances BlackRock Debt With Up to $140M Symbiotic Term Loan
AKBA sits 31% above its 52-week low of $0.361.
Summary
Akebia closed a senior secured term loan with Symbiotic Capital on November 12: a $60M initial tranche was fully funded and used to repay its $55M BlackRock facility in full, with up to $80M more available at Symbiotic's discretion. The loan runs 60 months, is interest-only for the full term with principal due at maturity, and carries a variable rate of the greater of WSJ Prime plus 4.5% or 11.5%. Management reaffirmed its cash runway guidance of at least two years, which matters given the Q3 10-Q warning that Vafseo revenue is expected to drop significantly in 2027 when TDAPA ends. This is non-dilutive capital that pushes out the BlackRock maturity and removes near-term refinancing pressure, though the 11.5% floor is an expensive cost of capital for a company with a $14.4M quarterly net loss. The 8-K with full loan terms is expected today.
At the time of this announcement, AKBA was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $131.7M. The 52-week trading range was $0.36 to $1.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.